Jobs at Medivation | Ladders
MedivationSan Francisco, CA

Why work for us

Medivation is an American biopharmaceutical company focused on rapid development of novel therapies to treat serious diseases for which there are limited treatment options. Medivation, in collaboration with Astellas, is currently developing enzalutamide for multiple stages of prostate cancer and for breast cancer. On August 31, 2012, Medivation and Astellas announced that the U.S. Food and Drug Administration (FDA) granted approval to XTANDI® (enzalutamide) capsules for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel. XTANDI is an oral, once-daily androgen receptor inhibitor. Medivation is headquartered in San Francisco, California, and it began operations in December 2004 with the acquisition of Medivation Neurology, Inc. The current CEO is David Hung. Pfizer announced it would acquire the company in August 2016. On March 3, 2010, Medivations stock dropped $27.15 per share to close at $13.10, a 67% one-day decline on volume of 45 million shares. In response, a security fraud class-action lawsuit was initiatied by Izard Nobel LLP, alleging that Medivation made false and misleading statements regarding the effectiveness of Dimebon as a treatment for Alzheimers disease, before being revealed that it did not meet primary and secondary goals in a Phase 3 trial for patients with mild to moderate Alzheimers disease.

Snapshot

Employees: 628
Market Cap: $13.5 billion
Revenue: $943 million
Net Income: $244.7 million
Jobs at Medivation
There are no jobs at the current time